Format

Send to

Choose Destination
J Oncol Pract. 2019 Nov;15(11):e925-e933. doi: 10.1200/JOP.18.00761. Epub 2019 Jul 3.

Incidence and Management of Olaratumab Infusion-Related Reactions.

Author information

1
Washington University in St Louis, St Louis, MO.
2
University of Arkansas for Medical Sciences, Little Rock, AR.
3
Mayo Clinic, Jacksonville, FL.
4
The University of Texas MD Anderson Cancer Care Center, Houston, TX.
5
Eli Lilly, Indianapolis, IN.
6
Memorial Sloan Kettering Cancer Center, New York, NY.

Abstract

PURPOSE:

Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab in clinical trials and postmarketing reports.

METHODS:

Data from patients exposed to olaratumab across nine clinical trials were reviewed for IRRs. Blood samples were also analyzed for pre-existing immunoglobulin E anti-galactose-α-1,3-galactose (anti-α-Gal) antibodies.

RESULTS:

In the clinical trials, IRRs were identified in 70 of 485 patients (14.4%). The most frequent symptoms included flushing, fever or chills, and dyspnea. For 68 of 70 patients (97.1%), the first IRR occurred during the first two cycles of treatment. Grade 3 or worse IRRs were reported in 11 patients (2.3%), all during the first infusion and usually within 15 minutes of the start of the infusion. One IRR-related fatality (0.2%) occurred in a nonpremedicated patient with grade 3 or worse cardiac comorbidities. There was an association between grade 3 or worse IRRs and pre-existing anti-α-Gal antibodies, with a trend toward higher IRR rates in US geographies known to have a higher prevalence of anti-α-Gal antibodies. IRRs in postmarketing reports were consistent in nature and severity with those in the clinical trials.

CONCLUSION:

Premedication with corticosteroids and antihistamines should occur in all patients before olaratumab infusion, as indicated in labels in the United States and the European Union. Patients receiving olaratumab should be monitored for IRRs in a setting where resuscitation equipment is available for the treatment of IRRs.

PMID:
31268811
PMCID:
PMC6851793
[Available on 2020-11-01]
DOI:
10.1200/JOP.18.00761

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center